Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Rhythm Pharmaceuticals, Inc. (RYTM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.24-0.90 (-8.88%)
At close: 1:00PM EST
9.49 +0.25 (+2.71%)
After hours: 03:45PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

    FDA sets PDUFA goal date of March 16, 2022BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bar

  • GlobeNewswire

    Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference

    BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 11:20 a.m. ET. A live webcast of the presentation will be available under “Events & Presentations”

  • GlobeNewswire

    Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results

    -- U.S. and EU regulatory filings submitted for IMCIVREE® (setmelanotide) for treatment of Bardet-Biedl and Alström syndromes; launch preparations underway ---- Delivered a total of 22 presentations at three major medical conferences -- -- New presentations include first-ever data showing improvements in health-related quality of life in rare genetic diseases of obesity ---- IMCIVREE third quarter net sales reach $1M ---- Management to Host Conference Call at 8:00 a.m. ET -- BOSTON, Nov. 02, 202

Advertisement
Advertisement